Jafron Biomedical Co Stock

Jafron Biomedical Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Jafron Biomedical Co (300529.SZ) as of Aug 17, 2026 is 15.22. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 29.80 — a change of -48.93% (lower).

EV/EBIT

15.22

YoY

-48.93%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Jafron Biomedical Co is 2026 15.22 . EV/EBIT (Enterprise Value to EBIT) of Jafron Biomedical Co was 2025 29.80 . It decreases by -48.93% lower compared to the previous year.

The Jafron Biomedical Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
46.71 base
Jan 1, 2020
53.62 base
Jan 1, 2021
31.25 base
Jan 1, 2022
24.45 base
Jan 1, 2023
33.35 base
Jan 1, 2024
22.13 base
Jan 1, 2025 (e)
19.36 base
Jan 1, 2026 (e)
15.75 base
YEARPRICE-TO-EBIT
2026 est 15.75
2025 est 19.36
2024 22.13
2023 33.35
2022 24.45
2021 31.25
2020 53.62
2019 46.71
2018 39.67
2017 45.81
2016 81.04
2015 -
2014 -
2013 -
Access this data via the Eulerpool API
Get Free API Key

Jafron Biomedical Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Jafron Biomedical Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Jafron Biomedical Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Jafron Biomedical Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Jafron Biomedical Co grows earnings faster than its peers.

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

EV/EBIT (Enterprise Value to EBIT) of Jafron Biomedical Co is 15.22 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Jafron Biomedical Co changed from 29.80 to 15.22, representing a -48.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Jafron Biomedical Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Jafron Biomedical Co